Derek So, MD, is a Staff Cardiologist and Clinician Investigator at the University of Ottawa Heart Institute and Associate Professor in the Department of Medicine at the University of Ottawa. He is the Program Director for the Adult Interventional Cardiology Program at the University of Ottawa Heart Institute. Dr. So leads the Ottawa region strategic research Innovation Cluster[v1] on Percutaneous Intervention (CAPITAL).
Background
Dr. Derek So earned his medical degree, cum laude, at the University of Toronto in 1997. He completed residencies in Internal Medicine at McMaster University in Hamilton, Ontario, and Cardiology at the University of Ottawa Heart Institute. He then went on to Fellowship training in Interventional Cardiology at the University of Ottawa Heart Institute. He furthered his training with a Master's in Clinical Epidemiology at the Harvard School of Public Health in Cambridge, Massachusetts.
Dr. So received his certification as a Fellow of the Royal College of Physicians and Surgeons of Canada (FRCPC) in Internal Medicine (2001) and in Cardiology (2003). He is also certified with the American Boards of Internal Medicine and Cardiovascular Diseases.
Dr. So is actively involved in teaching at both the undergraduate and postgraduate levels.
Dr. So has previously been on grant review panels for the Heart and Stroke Foundation of Canada (HSFC) (Committee 1a, 1b) and the Canadian Institutes of Health Research (CIHR) (Committee CID). In 2012, Dr. So was awarded the University of Ottawa Heart Institute Clinical Science Investigator of the Year. Dr. So’s research program has been funded by HSFC and CIHR.
Publications
See current publications list at PubMed.
See Research Gate profile.
Selected publications:
- Malhotra N, Abunassar J,. Wells GA, McPherson R, Fu A, Hibbert B, Labinaz M, Le May M, Dick A, Glover C, Froeschl M, Marquis JF, Tran L, Bernick J, Chong AY, So D. on behalf of the CArdiovascular Percutaneous Intervention TriAL (CAPITAL) investigators. A Pharmacodynamic Comparison of a Personalized Strategy for Anti-platelet Therapy versus Ticagrelor in Achieving a Therapeutic Window. Int J Cardiol. 2015.
- So DY, Wells GA, McPherson R, Labinaz M, Le May MR, Glover C, Dick AJ, Froeschl M, Marquis JF, Gollob MH, Tran L, Bernick J, Hibbert B, Roberts JD on behalf of the CAPITAL investigators. A Prospective Randomized Evaluation of a Pharmacogenomic Approach to Antiplatelet Therapy among Patients with ST-Elevation Myocardial Infarction: The RAPID STEMI Study. Pharmacogenomics J. 2015 Apr
- Roberts JD, Wells GA, Le May MR, Labinaz M, Glover C, Froeschl M, Dick A, Marquis JF, O’Brien E, Goncalves S, Druce I, Stewart A, Gollob MH, So DYF. Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomized, proof-of-concept trial. The Lancet. 2012 May 5; 379(9827):1705-11.
- So DYF, Roberts, JD. Overcoming Obstacles in Pharmacogenomic Strategies for Antiplatelet Drugs – Are We RAPID enough? Pharmacogenomics. July 2012; 13(10):1105-8.
- Goncalves SC, Labinaz M, Le May M, Glover C, Froeschl M, Marquis JF, O'Brien E, Shukla D, Ruchin P, Sookur D, Ha A, So D. Usefulness of mean platelet volume as a biomarker for long-term outcomes after percutaneous coronary intervention. Am J Cardiol. 2011 Jan 15;107(2):204-9.
- So DY, Cook EF, Le May M, Glover C, Williams W, Ha A, Davie RF, Froeschl M, Marquis JF, O’Brien E, Labinaz M. Association of Aspirin Dosage to Clinical Outcomes after Percutaneous Coronary Intervention: Observations from the Ottawa Heart Institute PCI Registry. J Invasive Cardiol. 2009. 21(3):121-7.
- Le May MR, So DY, Dionne R, Glover CA, Froeschl MP, Wells GA, Davies RF, Sherrard HL, Maloney J, Marquis JF, O’Brien ER, Trickett J, Poirer P, Ryan SC, Ha A, Joseph PG, Labinaz M. A Citywide Protocol for Primary PCI in ST-segment Elevation Myocardial Infarction. New Engl J Medicine. 2008. 358(3):231-40